Presented by Steve Cammarn, Ph.D.
Product development in the dietary supplement industry has never been more competitive. With new companies and products arriving in the marketplace at rapid speed, the pressure is on to develop something new and exciting for the consumer in order to stay ahead of the competition.
When developing new products, one area that cannot be overlooked is that of regulatory compliance with the Dietary Supplement Health and Education Act of 1994 (DSHEA), and FDA’s Good Manufacturing Practice requirements for dietary supplements per 21 CFR 111, Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, and appropriate labeling of the dietary supplement product in accordance to 21 CFR 101, Food Labeling.
Join EAS Independent Consultant, Steve Cammarn, Ph.D., for a discussion on principles and techniques for a phased-approach of the development of vitamin, mineral, and supplements, incorporating product design, process development, supply chain establishment, and qualification. Dr. Cammarn weaves together the scientific principles as well as the overarching regulatory requirements that must be met for commercial and compliance success.<
About the Presenter
Steve Cammarn, Ph.D.
Stephen Cammarn, Ph.D., is an independent consultant with EAS Consulting Group. Previously, Dr. Cammarn served 34 years as a leader in healthcare R&D and Quality Assurance with The Procter & Gamble Company. Stephen led and managed organizations that spanned the Americas, EMEA, and Asia, responsible for global Pharmaceutical Development and Quality Assurance for healthcare products. He has expertise in formulation, design, process, technical support, quality and regulatory aspects of pharmaceuticals, OTC medicines; vitamins, minerals and supplements; oral care products and devices, and foods. Stephen also holds numerous patents and has developed, obtained FDA approval for and launched numerous new products, and has led work to remediate contractor firms after FDA observations and Warning Letters. Stephen also has extensive experience in due diligence, joint ventures, and partnerships. Stephen holds an undergraduate degree in Chemical Engineering and a Ph.D. in Industrial Pharmacy. Stephen has also served as adjunct faculty with the University of Cincinnati College of Pharmacy, as well as on numerous community boards.